| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 03/07/2002 | US20020028252 Multifluid atomization of a dispersed system of a biologically active agent and a solvent to produce droplets; freezing the droplets; lyophilizing the frozen droplets obtain microstructures capable of being further fragmented |
| 03/07/2002 | US20020028244 Biodegradable neurotoxin implant |
| 03/07/2002 | US20020028236 Erythropoietin or derivatives that cause bone marrow cells to increase production of reticulocytes and erythrocytes; hydrogenated lecithin that may be hydrogenated; cholesterol or a derivative; phosphate buffer |
| 03/07/2002 | US20020028216 Controlled release implantable drug delivery system composed of a plurality of botulinum toxin-incorporating polymeric microspheres. |
| 03/07/2002 | US20020028214 Hyperconcentration of hepatitis virus C neutralizing antibodies |
| 03/07/2002 | US20020028212 Recombinant viruses coding for a glutamate decarboxylase (gad) activity |
| 03/07/2002 | US20020028208 Nucleic acid encoding feline cd86 |
| 03/07/2002 | US20020028205 May be comprised of a heavily glycosylated mucin part, which mediates binding to selectins, such as PSGL-1; absorber to prevent a hyperacute rejection of a xenotransplant |
| 03/07/2002 | US20020028204 Inhibits ristocetin-induced platelet aggregation), botrocetin-induced platelet aggregation, and shear stress-induced platelet aggregation of human platelet, and which does not express bleeding action |
| 03/07/2002 | US20020028203 T cell inhibitory receptor compositions and uses thereof |
| 03/07/2002 | US20020028202 Common gamma chain blocking agents |
| 03/07/2002 | US20020028201 Element A, which is a plastic with a group derived from a carboxy acid (e.g., an acrylate polymer), is hydrogen bonded to an element B (e.g., polyalkylene glycol; coupling physiologically and/or pharmacologically active substances |
| 03/07/2002 | US20020028199 Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein C (APC) |
| 03/07/2002 | US20020028198 DNA coding for the protein; useful for a prophylactic or therapeutic agent for hypoglycemia. |
| 03/07/2002 | US20020028195 Viruses for the treatment of cellular proliferative disorders |
| 03/07/2002 | US20020028194 DNA encoding a transcription unit comprising a transgene linked to expression control sequences, a an adenovirus E3 region, and a modified E4 region containing E4ORF3, and at least one other portion of an adenovirus E4 region |
| 03/07/2002 | US20020028181 Polyacid/polyalkylene oxide foams and gels and methods for their delivery |
| 03/07/2002 | DE10041560A1 New peptide from the alpha1 adrenergic receptor, useful for diagnosis and treatment of psoriasis, and also for raising specific antibodies |
| 03/07/2002 | DE10041238A1 Verfahren zur Identifizierung spezifisch spaltbarer peptide und Verwendung solcher Peptidsequenzen A method for identifying specific cleavable peptide and use of such peptide sequences |
| 03/07/2002 | DE10040592A1 Composition for oral administration of drugs, e.g. peptidomimetics or sparingly soluble antibiotics, containing hydrogel copolymer of unsaturated acid and polyalkylene glycol ester as resorption improver |
| 03/07/2002 | DE10038111A1 New G protein coupled receptors, useful for diagnosis, treatment and prevention of skin and wound-healing disorders, also related nucleic acid and antibodies |
| 03/07/2002 | CA2697205A1 Peptidomimetic protease inhibitors |
| 03/07/2002 | CA2457162A1 Electroprocessed fibrin-based matrices and tissues |
| 03/07/2002 | CA2424052A1 Packaging of positive-strand rna virus replicon particles |
| 03/07/2002 | CA2421122A1 Novel nucleic acids and polypeptides |
| 03/07/2002 | CA2420944A1 Inhibition of cmv infection and dissemination |
| 03/07/2002 | CA2420902A1 18 human secreted proteins |
| 03/07/2002 | CA2420900A1 Thrombomodulin analogs for use in recovery of signal cord injury |
| 03/07/2002 | CA2420867A1 Methods for enhancing the efficacy of cancer therapy |
| 03/07/2002 | CA2420856A1 Control of crop pests and animal parasites through direct neuronal uptake |
| 03/07/2002 | CA2420852A1 Modulators of intermediate conductance calcium-activated potassium (ikca) channel activity for treating sexual dysfunction |
| 03/07/2002 | CA2420832A1 Methods and reagents for protease inhibition |
| 03/07/2002 | CA2420765A1 Anti-angiogenic peptides |
| 03/07/2002 | CA2420696A1 Isolated human drug-metabolizing proteins, nucleic acid molecules and uses thereof |
| 03/07/2002 | CA2420667A1 Quinoline-(c=o)-(di-,tri- and tetrapeptide) derivatives as caspase inhibitors |
| 03/07/2002 | CA2420659A1 Genes expressed in the cell cycle |
| 03/07/2002 | CA2420652A1 Vertebrate intestinal protein which absorbs cholesterol, and the use of this protein for identifying inhibitors of intestinal cholesterol transport |
| 03/07/2002 | CA2420593A1 Tumor necrosis factor receptors 6.alpha. and 6.beta. |
| 03/07/2002 | CA2420392A1 17 human secreted proteins |
| 03/07/2002 | CA2420103A1 Modulation of fas and fasl expression |
| 03/07/2002 | CA2420062A1 Erbb4 antagonists |
| 03/07/2002 | CA2419935A1 Collagen/polysaccharide bilayer matrix |
| 03/07/2002 | CA2419606A1 Lung surfactant compositions with dynamic swelling behaviour |
| 03/07/2002 | CA2419567A1 Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma |
| 03/07/2002 | CA2419561A1 Method for treating the central nervous system by administration of igf structural analogs |
| 03/07/2002 | CA2419480A1 Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers |
| 03/07/2002 | CA2419472A1 Sgk2 and sgk3 used as diagnostic and therapeutic targets |
| 03/07/2002 | CA2419342A1 G-protein coupled receptors |
| 03/07/2002 | CA2418041A1 Pyrrolidine derivatives and their use as chymase inhibitor |
| 03/06/2002 | EP1184454A2 Nav2 channel gene-deficient non-human animals |
| 03/06/2002 | EP1184035A2 Use of growth hormone secretagogues for treatment of physical performance decline |
| 03/06/2002 | EP1184034A2 Oral drug composition containing a verapamil derivative as a drug-absorption promotor |
| 03/06/2002 | EP1183392A1 Diagnosis, prognosis and treatment of cancer related to the barx2 gene |
| 03/06/2002 | EP1183386A1 Tm4sf receptors |
| 03/06/2002 | EP1183384A1 Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders |
| 03/06/2002 | EP1183374A1 Recombinant fusion protein, (vaccine) composition containing the same and method for the production thereof |
| 03/06/2002 | EP1183371A2 Composition designed for implementing an antitumoral or antiviral treatment in a mammal |
| 03/06/2002 | EP1183370A2 Human oxidoreductase proteins |
| 03/06/2002 | EP1183368A2 Proteinfragmente die verschiedene epitope der hpv proteine e6 und e7 umfassen, ihre herstellung und verwendungen insbesondere zur impfung |
| 03/06/2002 | EP1183367A1 Cytotoxic t-cell epitopes of the papillomavirus l1-protein and use thereof in diagnostics and therapy |
| 03/06/2002 | EP1183364A1 Groel muteins with improved stability |
| 03/06/2002 | EP1183361A1 Gene therapy of pulmonary disease |
| 03/06/2002 | EP1183360A2 Modified cytokine for its stabilisation |
| 03/06/2002 | EP1183359A2 Nucleic acids and proteins with interferon-beta activity |
| 03/06/2002 | EP1183358A1 Targeted angiogenesis |
| 03/06/2002 | EP1183357A2 Vascular endothelial growth factor dimers |
| 03/06/2002 | EP1183355A1 T-bet compositions and methods of use thereof |
| 03/06/2002 | EP1183354A2 Methods of reducing factor viii clearance and compositions therefor |
| 03/06/2002 | EP1183353A1 Modified chimeric polypeptides with improved pharmacokinetic properties |
| 03/06/2002 | EP1183352A1 Vascular endothelial growth factor variants |
| 03/06/2002 | EP1183351A1 Phospholipid transfer protein |
| 03/06/2002 | EP1183348A2 Compositions for the treatment and diagnosis of breast cancer and methods for their use |
| 03/06/2002 | EP1183344A2 Adam polynucleotides and polypeptides |
| 03/06/2002 | EP1183333A1 Methods of using rnase p reaction mechanisms of action |
| 03/06/2002 | EP1183330A1 Kv10.1, A NOVEL VOLTAGE-GATED POTASSIUM CHANNEL FROM HUMAN BRAIN |
| 03/06/2002 | EP1183274A1 Method and compounds for inhibiting activity of serine elastases |
| 03/06/2002 | EP1183273A1 C-cam as an angiogenesis inhibitor |
| 03/06/2002 | EP1183272A2 49 human secreted proteins |
| 03/06/2002 | EP1183271A1 Polymer conjugates of hedgehog proteins and uses |
| 03/06/2002 | EP1183267A1 Retro-inverso peptides derived from interleukin-6 |
| 03/06/2002 | EP1183266A1 Retro-inverso peptides derived from leukemia inhibitory factor |
| 03/06/2002 | EP1183051A2 Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
| 03/06/2002 | EP1183047A2 Pharmaceutical preparation |
| 03/06/2002 | EP1183046A1 Aminotetralin derivative for the therapy of cardiovascular diseases |
| 03/06/2002 | EP1183043A2 Medicament for localised application, containing fibrinogen, thrombin, transglutaminases and proteinase inhibitors |
| 03/06/2002 | EP1183042A2 Methods for treating diabetes |
| 03/06/2002 | EP1183041A2 Ligand for cd7, and methods for use thereof |
| 03/06/2002 | EP1183040A1 Therapeutic use of an inhibitor of a hedgehog or a hedgehog-related signalling pathway |
| 03/06/2002 | EP1183034A1 Modulators of methylation for control of bacterial virulence |
| 03/06/2002 | EP1183031A1 Quinoxaline containing medicaments for post exposure prophylaxis of an hiv infection |
| 03/06/2002 | EP1183020A2 Use of(-)(3-trihalomethylphenoxy) (4-halophenyl)acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidaemia and hyperuricaemia |
| 03/06/2002 | EP1183011A1 Method of treating angina and/or anginal equivalents, and pharmaceutical compositions and kit related thereto |
| 03/06/2002 | EP1183010A2 Implantable gel compositions and method of manufacture |
| 03/06/2002 | EP1182939A1 The combined use of triglycerides containing medium chain fatty acids and exogenous lipolytic enzymes as feed supplements |
| 03/06/2002 | EP1182929A1 Osteonectin based toxic gene therapy for the treatment of calcified tumors and tissues |
| 03/06/2002 | EP0942743B1 Topical preparation for introducing peptidaceous pharmacons in living organisms |
| 03/06/2002 | EP0938505B1 Anti-endoglin monoclonal antibodies and their use in anti-angiogenesis therapy |
| 03/06/2002 | EP0873133B1 Biologically active composition comprising cyclosporine |
| 03/06/2002 | EP0848757B1 The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells |
| 03/06/2002 | EP0785797B1 A pharmaceutical formulation comprising a growth hormone and leucine |